Lincoln National Corp’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-14,180
| Closed | -$1.04M | – | 452 |
|
|
2024
Q1 | $1.04M | Buy |
14,180
+1,402
| +11% | +$108K | 0.02% | 512 |
|
|
2023
Q4 | $1.04M | Buy |
12,778
+3,785
| +42% | +$295K | 0.02% | 451 |
|
|
2023
Q3 | $674K | Buy |
8,993
+1,397
| +18% | +$107K | 0.01% | 506 |
|
|
2023
Q2 | $585K | Sell |
7,596
-131
| -2% | -$10.4K | 0.01% | 548 |
|
|
2023
Q1 | $641K | Sell |
7,727
-392
| -5% | -$32.5K | 0.01% | 506 |
|
|
2022
Q4 | $697K | Sell |
8,119
-3,756
| -32% | -$297K | 0.02% | 447 |
|
|
2022
Q3 | $733K | Buy |
11,875
+1,961
| +20% | +$124K | 0.02% | 396 |
|
|
2022
Q2 | $613K | Buy |
9,914
+2,072
| +26% | +$128K | 0.01% | 442 |
|
|
2022
Q1 | $466K | Buy |
7,842
+885
| +13% | +$56.6K | 0.01% | 554 |
|
|
2021
Q4 | $505K | Sell |
6,957
-760
| -10% | -$52.3K | 0.01% | 521 |
|
|
2021
Q3 | $539K | Buy |
7,717
+369
| +5% | +$25.9K | 0.01% | 478 |
|
|
2021
Q2 | $506K | Buy |
7,348
+1,574
| +27% | +$105K | 0.01% | 490 |
|
|
2021
Q1 | $374K | Buy |
5,774
+21
| +0.4% | +$1.35K | 0.01% | 537 |
|
|
2020
Q4 | $335K | Sell |
5,753
-1,000
| -15% | -$60.3K | 0.01% | 540 |
|
|
2020
Q3 | $427K | Buy |
6,753
+354
| +6% | +$24.5K | 0.01% | 414 |
|
|
2020
Q2 | $492K | Buy |
6,399
+779
| +14% | +$59.7K | 0.02% | 377 |
|
|
2020
Q1 | $421K | Buy |
5,620
+1,434
| +34% | +$99.1K | 0.02% | 367 |
|
|
2019
Q4 | $272K | Sell |
4,186
-124
| -3% | -$8.07K | 0.01% | 516 |
|
|
2019
Q3 | $274K | Buy |
4,310
+150
| +4% | +$9.8K | 0.01% | 464 |
|
|
2019
Q2 | $281K | Sell |
4,160
-396
| -9% | -$26.1K | 0.01% | 434 |
|
|
2019
Q1 | $296K | Buy |
4,556
+808
| +22% | +$53.7K | 0.01% | 392 |
|
|
2018
Q4 | $234K | Sell |
3,748
-621
| -14% | -$43.4K | 0.01% | 402 |
|
|
2018
Q3 | $337K | Sell |
4,369
-762
| -15% | -$57.5K | 0.01% | 334 |
|
|
2018
Q2 | $364K | Sell |
5,131
-732
| -12% | -$51.7K | 0.01% | 321 |
|
|
2018
Q1 | $442K | Sell |
5,863
-7,343
| -56% | -$584K | 0.02% | 281 |
|
|
2017
Q4 | $946K | Buy |
13,206
+7,367
| +126% | +$559K | 0.03% | 242 |
|
|
2017
Q3 | $473K | Sell |
5,839
-1,264
| -18% | -$96.7K | 0.02% | 226 |
|
|
2017
Q2 | $502K | Sell |
7,103
-399
| -5% | -$26.6K | 0.02% | 196 |
|
|
2017
Q1 | $510K | Sell |
7,502
-139
| -2% | -$9.77K | 0.03% | 184 |
|
|
2016
Q4 | $547K | Sell |
7,641
-3,629
| -32% | -$270K | 0.03% | 167 |
|
|
2016
Q3 | $892K | Buy |
11,270
+1,268
| +13% | +$103K | 0.05% | 128 |
|
|
2016
Q2 | $834K | Buy |
10,002
+1,429
| +17% | +$127K | 0.05% | 127 |
|
|
2016
Q1 | $788K | Buy |
8,573
+917
| +12% | +$82.7K | 0.06% | 124 |
|
|
2015
Q4 | $738K | Buy |
7,656
+382
| +5% | +$39.7K | 0.06% | 98 |
|
|
2015
Q3 | $715K | Buy |
7,274
+497
| +7% | +$55.2K | 0.06% | 101 |
|
|
2015
Q2 | $801K | Buy |
6,777
+1,295
| +24% | +$142K | 0.06% | 99 |
|
|
2015
Q1 | $538K | Buy |
5,482
+1,086
| +25% | +$110K | 0.04% | 114 |
|
|
2014
Q4 | $414K | Sell |
4,396
-414
| -9% | -$42.8K | 0.04% | 115 |
|
|
2014
Q3 | $512K | Buy |
4,810
+60
| +1% | +$5.88K | 0.05% | 100 |
|
|
2014
Q2 | $394K | Buy |
4,750
+1,000
| +27% | +$77.8K | 0.04% | 106 |
|
|
2014
Q1 | $266K | Buy |
+3,750
| New | +$294K | 0.04% | 98 |
|
Other funds holding GILD
Lincoln National Corp's GILD Position: Q2 2024 in Review
Lincoln National Corp sold out of Gilead Sciences (GILD) in Q2 2024, closing a stake of 14,180 shares — an estimated $1.04M sold.
Lincoln National Corp first reported a position in GILD in Q1 2014 and held it in 41 quarters. The position peaked at $1.04M in Q1 2024. 1,678 funds tracked by Wall St. Rank hold GILD as of Q2 2024.
- Lincoln National Corp reported no remaining Gilead Sciences position as of Q2 2024 after selling out during the quarter.
- Lincoln National Corp sold 14,180 Gilead Sciences shares in Q2 2024, an estimated $1.04M.
- Lincoln National Corp first reported a position in Gilead Sciences in Q1 2014 and held it in 41 quarters.
- Lincoln National Corp's Gilead Sciences position peaked at $1.04M in Q1 2024.
- 1,678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.
Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.